Kerrisdale Capital Issues Negative Report on Pulse Biosciences, Inc. and Announces Conference Call
- Pulse claims its technology can eliminate tumors and trigger immune responses, but clinical evidence demonstrates worst-in-class efficacy
- Research sponsored by Pulse confirms that its technology cannot even reliably kill cancer cells in vitro
- A near-identical device that has been FDA-approved for more than 10 years generates paltry revenue
NEW YORK, May 9, 2017 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a report explaining its short position in Pulse Biosciences, Inc. (NASDAQ:PLSE), a ~$400 million early-stage medical-device company developing a technology that applies strong electrical fields for short periods of time in order to induce cell death. Pulse's stock price has increased six-fold since its May 2016 IPO despite poor preclinical and clinical results. Kerrisdale believes that Pulse's technology is inferior to alternatives and will struggle to generate any meaningful revenues in the future.
The full report can be found at http://kerr.co/plse.
Kerrisdale has a short position in Pulse Biosciences and stands to benefit if its share price falls.
Conference Call Schedule
Kerrisdale will host a conference call on Tuesday, May 9, 2017 at 10:30am ET to discuss the Pulse Biosciences report.
To participate in the conference call, dial 888-567-1602 (US and Canada) or 862-255-5346 (international) and reference the Kerrisdale Capital call.
About Kerrisdale Capital
Kerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.
Contact
Agnes Cao
Kerrisdale Capital
[email protected]
212-257-4385
Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.
SOURCE Kerrisdale Capital Management, LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article